Celularity Shares T-Cell Platform Data on Tumors at ASCO Meeting

Celularity Inc., a leader in regenerative and cellular medicine, has unveiled promising in vivo data on PT-CD16VS, their genetically modified allogeneic cell therapy derived from human placental T (P-T) cells. This announcement was made at the ASCO Annual Meeting in Chicago, highlighting PT-CD16VS's ability to work in combination with various monoclonal antibodies to target a broad range of cancers.

Celularity’s PT-CD16VS, a preclinical T-Cell asset, has demonstrated significant efficacy both in vitro and in vivo. The company is leveraging a “universal receptor” strategy, whereby genetically modified T-cells expressing a proprietary CD16 can be paired with multiple approved antibodies. This approach aims to address numerous cancers and other health conditions. Evidence of PT-CD16VS's activity, particularly when combined with trastuzumab against HER2-positive cancers, was initially presented at the AACR meeting in April. This new data expands on that foundation, showcasing the potential of PT-CD16VS across various hematological and solid tumors.

Dr. Robert Hariri, CEO and Founder of Celularity, emphasized the importance of these findings. He noted that the placental-derived cell therapy platform could provide effective solutions to challenging cancers while circumventing some of the limitations associated with traditional cell therapies, such as antigen escape and tolerance issues. Additionally, Celularity is pushing forward its pipeline to tackle aging-related health issues, including cellular senescence, beyond their cancer-targeting efforts. The company's expertise and advanced capabilities in cell therapy are evident in their state-of-the-art manufacturing facility, where they continue to innovate and engineer these therapeutic cells.

Celularity Inc. stands out in the regenerative and cellular medicine landscape due to its focus on developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies. These therapies are drawn from postpartum placentas and are aimed at treating a range of aging-related diseases, degenerative conditions, cancer, and immune disorders. Celularity employs mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and genetically modified and unmodified natural killer (NK) cells in its therapeutic programs. The company's unique approach, which harnesses the biology and availability of the placenta, is paving the way for therapeutic solutions that meet significant global needs for effective, accessible, and affordable therapies.

The announcement also included a discussion on the broader implications of Celularity’s PT-CD16VS product candidate. The potential for this candidate to be combined with various monoclonal antibodies could significantly impact treatment options for multiple hematological and solid tumors. Furthermore, Celularity's placental-derived cell therapy platform may offer solutions to difficult-to-treat cancers while avoiding some of the traditional challenges, such as antigen escape and tolerability issues. The company’s ongoing efforts to advance its pipeline beyond cancer into aging-related healthcare challenges underscore its commitment to innovation and addressing unmet medical needs.

Celularity Inc. is committed to continuous innovation and development in the field of cellular therapies. By leveraging the unique properties of placental-derived cells, the company aims to provide groundbreaking solutions for a variety of challenging health conditions. Their ongoing research and development efforts are a testament to their leadership in the field and their dedication to improving patient outcomes through advanced cellular medicine.